Tuesday, July 16, 2024

June 2024 Milestones for Institute for Clinical and Economic Review

Similar articles

In June, the Institute for Clinical and Economic Review (ICER) released a series of significant evaluations and analyses aimed at assessing the effectiveness and accessibility of various therapies and insurance coverage policies. ICER’s mission is to evaluate the clinical and economic value of healthcare interventions to improve patient outcomes and inform healthcare decision-making. The following summary provides a detailed overview of the key updates from ICER, highlighting their ongoing efforts to enhance the understanding of treatment benefits and ensure fair access to medications.

The Institute for Clinical and Economic Review evaluated the use of MDMA (ecstasy) as a therapy for post-traumatic stress disorder (PTSD). Their findings indicated that there is insufficient evidence to determine the therapy’s benefits compared to other treatments or no treatment at all. Additionally, ICER did not assess the cost-effectiveness of this therapy due to the lack of information on its pricing.

ICER is conducting a fourth-year analysis to evaluate how well major insurers’ prescription drug coverage aligns with fair access standards. These standards focus on factors such as affordability, eligibility, step therapy requirements, and provider limitations. This year, ICER will examine policies from leading commercial insurers and the Department of Veterans Affairs. They will also analyze data on coverage denials, appeals, and patient costs for drugs reviewed in 2022. The goal of this analysis is to assess how well these insurers’ policies meet fair access criteria across different medications, conditions, and insurers.

The updates from ICER in June underscore their commitment to evaluating the effectiveness and accessibility of healthcare treatments and policies. Their findings on MDMA therapy for PTSD highlight the need for further research to establish its benefits. Meanwhile, the ongoing analysis of prescription drug coverage policies aims to ensure that insurance providers adhere to fair access standards, thereby improving patient access to necessary medications. These efforts by ICER are crucial in guiding healthcare decisions and promoting equitable access to effective treatments.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article